多瑞医药
(301075)
| 流通市值：35.75亿 | | | 总市值：50.54亿 |
| 流通股本：5660.00万 | | | 总股本：8000.00万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 95,655,393.08 | 32,431,205.53 | 154,176,460.28 | 136,998,003.2 |
| 营业收入 | 95,655,393.08 | 32,431,205.53 | 154,176,460.28 | 136,998,003.2 |
| 二、营业总成本 | 137,708,660.18 | 54,224,700.54 | 274,302,230.06 | 244,884,906.84 |
| 营业成本 | 84,938,279.6 | 29,986,080.53 | 141,576,096.97 | 130,655,304.23 |
| 税金及附加 | 2,105,638.53 | 864,884.27 | 3,505,889.71 | 2,671,086.28 |
| 销售费用 | 4,371,505.51 | 2,531,255.22 | 23,098,323.98 | 18,263,585.99 |
| 管理费用 | 26,228,455.13 | 12,553,612.62 | 56,896,573.23 | 39,544,732.33 |
| 研发费用 | 13,420,527.57 | 4,937,772.84 | 32,410,858.18 | 40,603,237.21 |
| 财务费用 | 6,644,253.84 | 3,351,095.06 | 16,814,487.99 | 13,146,960.8 |
| 其中:利息费用 | 6,603,947.79 | 3,336,010.64 | 17,936,231.42 | - |
| 其中:利息收入 | 28,866.01 | 18,980.83 | 1,226,644.74 | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 38,583.78 | -56,833.33 |
| 加:投资收益 | 40,205,255.59 | -263,940.04 | 852,610.79 | 1,623,847.67 |
| 资产处置收益 | 242,762.47 | -50,476.75 | -105,451.29 | 9,561.89 |
| 资产减值损失(新) | -642,497.9 | -594,367.33 | -5,992,360.28 | -1,141,521.64 |
| 信用减值损失(新) | 2,785,739.39 | 1,757,506.65 | -11,837,463.65 | -9,699,817.7 |
| 其他收益 | 4,175,826.04 | 2,102,566.39 | 8,795,778.76 | 6,834,353.9 |
| 四、营业利润 | 4,713,818.49 | -18,842,206.09 | -128,374,071.67 | -110,317,312.85 |
| 加:营业外收入 | 1,917,901.21 | 1 | 18,844.36 | 38,217.61 |
| 减:营业外支出 | 383,793.11 | 109,759.17 | 3,002,204.39 | 872,488.97 |
| 五、利润总额 | 6,247,926.59 | -18,951,964.26 | -131,357,431.7 | -111,151,584.21 |
| 减:所得税费用 | 3,007,260.08 | 62,272.79 | 1,043,958.53 | 1,547,090.25 |
| 六、净利润 | 3,240,666.51 | -19,014,237.05 | -132,401,390.23 | -112,698,674.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 3,240,666.51 | -19,014,237.05 | -132,401,390.23 | -112,698,674.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 11,529,388.32 | -13,967,969.05 | -102,169,763.37 | -79,727,687.11 |
| 少数股东损益 | -8,288,721.81 | -5,046,268 | -30,231,626.86 | -32,970,987.35 |
| 扣除非经常损益后的净利润 | -33,437,648.16 | -14,447,006.27 | -107,047,608.69 | -84,948,541.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | -0.18 | -1.29 | -1.01 |
| (二)稀释每股收益 | 0.15 | -0.18 | -1.29 | -1.01 |
| 八、其他综合收益 | 200,000 | - | - | - |
| 归属于母公司股东的其他综合收益 | 200,000 | - | - | - |
| 九、综合收益总额 | 3,440,666.51 | -19,014,237.05 | -132,401,390.23 | -112,698,674.46 |
| 归属于母公司股东的综合收益总额 | 11,729,388.32 | -13,967,969.05 | -102,169,763.37 | -79,727,687.11 |
| 归属于少数股东的综合收益总额 | -8,288,721.81 | -5,046,268 | -30,231,626.86 | -32,970,987.35 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-04-29 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |